We have previously used this method to measure the baseline T cell immunity of patients with Progressive Multifocal Leukoencephalopathy (PML) against John Cunningham (JC) Polyomavirus antigens LT and VP1 as a marker to predict the likelihood clinical response to PD-1 blockade (39). Here, LTA is linked to progressive multifocal leukoencephalopathy.